Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Símbolo de cotizaciónPGEN
Nombre de la empresaPrecigen Inc
Fecha de salida a bolsaAug 08, 2013
Director ejecutivoSabzevari (Helen)
Número de empleados143
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 08
Dirección20374 Seneca Meadows Parkway
CiudadGERMANTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20876
Teléfono13015569900
Sitio Webhttps://precigen.com/
Símbolo de cotizaciónPGEN
Fecha de salida a bolsaAug 08, 2013
Director ejecutivoSabzevari (Helen)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos